Propagated circulating tumor cells uncovers the role of NFκB and COP1 in metastasis

Jerry Xiao, Utsav Sharma, Abolfazl Arab, Sohit Miglani, Sonakshi Bhalla, Shravanthy Suguru, Robert K. Suter, Reetu Mukherji, Marc E. Lippman, Paula R. Pohlmann, Jay Zeck, John L. Marshall, Benjamin A. Weinberg, Aiwu Ruth He, Marcus Smith Noel, Richard Schlegel, Hani Goodarzi, Seema AgarwalbioRxiv 2022 · DOI

TL;DR

Researchers have developed a high-efficiency platform to isolate and expand ultra-rare circulating tumor cells (CTCs) from patient blood, enabling the creation of robust mouse models (CDXs) that mimic human metastasis. Their analysis reveals a universal "pan-cancer" role for NF-κB signaling and identifies mutations in the protein COP1 as a potential key driver of cancer's spread.

What Problem Does This Paper Address?

Metastasis—the spread of cancer from a primary tumor to distant organs—is responsible for roughly 90% of cancer-associated deaths. The "seeds" of this process are Circulating Tumor Cells (CTCs), which break off from tumors and travel through the bloodstream.

However, CTCs are incredibly rare (often fewer than 10 cells per mL of blood), making them nearly impossible to study directly. Previous attempts to grow these cells in the lab or in mice (xenografts) usually required hundreds of cells to start, a luxury most patients don't have. This paper tackles the "needle in a haystack" problem by creating a reliable way to expand these rare cells into a population large enough for deep genetic and functional study.

Methods

The authors employed a multi-step "expansion" strategy:

  1. Unbiased Isolation: Instead of using antibodies to "grab" specific cells (which can miss certain cancer types), they used a density-dependent method (Ficoll-Paque) to separate CTCs from whole blood.
  2. Ex Vivo Expansion: The isolated cells were cultured in the lab for 14–28 days. This "pre-growth" phase increased cell numbers from a handful to thousands.
  3. CDX Generation: These expanded CTCs were injected into immunodeficient mice to create CTC-derived xenografts (CDXs).
  4. Multi-Omics Analysis: The team performed bulk RNA-sequencing and Whole-Exome Sequencing (WES) on the original patient blood, the cultured cells, the mouse tumors, and the resulting metastases to track how the cancer evolved.

Datasets

  • Patient Samples: 25 liquid biopsies from 21 patients with metastatic lung, colon, and pancreatic cancers.
  • Validation Data: The researchers used the TCGA (The Cancer Genome Atlas) pan-cancer atlas to correlate their findings with real-world clinical outcomes and survival rates.
  • Reference Data: Whole blood from healthy donors (HD) served as a baseline control.

Key Insights and Ideas

  • The Expansion Advantage: By growing CTCs ex vivo first, the researchers achieved a 92% success rate in establishing cultures, far higher than previous methods. This allowed them to create CDX models from patients with very low initial CTC counts.
  • NF-κB as a Pan-Cancer Hub: Across different types of cancer (lung, colon, pancreatic), the NF-κB signaling pathway was consistently enriched in metastatic cells. This suggests that while tumors are diverse, the "machinery" they use to spread might be a universal target for therapy.
  • The 5-Gene "High-Risk" Signature: They identified a specific signature (BCAR1, COL1A1, IGSF3, RRAD, and TFPI2) that was upregulated in all CTC models and strongly correlated with poorer disease-free survival in the TCGA database.
  • COP1 as a Driver: Perhaps the most striking find was the identification of de novo mutations in COP1 (constitutive photomorphogenesis protein 1) across all four CDX models. This suggests COP1 inactivation might be a selective pressure that helps cells survive the journey through the blood and colonize new organs.

Key Results

  • Robust Modeling: All "1st generation" CDX models developed palpable tumors within ~32 days and showed visible macro-metastases in organs like the spleen, liver, and lungs within 2–3 months—significantly faster than many traditional models.
  • Genetic Fidelity: Despite the expansion process, ≥80% of mutations found in patient tissue were recovered in the CTC and CDX models, proving the models are faithful representatives of the patient's disease.
  • Organ-Specific Signatures: The study identified unique gene sets associated with metastasis to specific organs (e.g., 60 unique genes for liver metastasis, including MTOR and HIF1A).

Limitations and Future Work

While the platform is highly successful at growing cells, the authors acknowledge that the ex vivo culture environment might select for a "highly aggressive" subpopulation of cells, potentially masking some of the original tumor's heterogeneity.

The deep CDX analysis was also limited to a small cohort of four patients. Future work will need to scale this technology to larger patient groups and utilize single-cell RNA sequencing to understand how the transition from blood to culture to mouse affects the individual "personalities" of cancer cells within a single patient.

Summary updated

Abstract

Abstract Circulating tumor cells (CTCs), a population of cancer cells that represents the seeds of metastatic nodules, are a promising model system for studying metastasis. However, expansion of patient-derived CTCs ex vivo is challenging and dependent on the collection of high numbers of CTCs, which are ultra-rare. Here, we report the development of a combined CTC and CTC-derived xenograft (CDX) platform for expanding and studying patient-derived CTCs from metastatic colon, lung, and pancreatic cancers. Propagated CTCs yielded a highly aggressive population of cells that could be used to routinely and robustly establish primary tumors and metastatic lesions in CDXs. Differential gene analysis of the resultant CTC models emphasized a role for NF-kB signaling as a pan-cancer signaling pathway involved in metastasis. Furthermore, metastatic CTCs were identified through a prospective 5-gene signature ( BCAR1, COL1A1, IGSF3, RRAD, and TFPI2 ). Whole-exome sequencing of CDX models and metastases further identified mutations in constitutive photomorphogenesis protein 1 ( COP1 ) as a potential driver of metastasis. These findings illustrate the utility of the combined patient-derived CTC model and provide a glimpse of the promise of CTCs in identifying drivers of cancer metastasis.
BibTeX
@misc{xiao2022propagated,
  author = {Jerry Xiao and Utsav Sharma and Abolfazl Arab and Sohit Miglani and Sonakshi Bhalla and Shravanthy Suguru and Robert K. Suter and Reetu Mukherji and Marc E. Lippman and Paula R. Pohlmann and Jay Zeck and John L. Marshall and Benjamin A. Weinberg and Aiwu Ruth He and Marcus Smith Noel and Richard Schlegel and Hani Goodarzi and Seema Agarwal},
  title = {{Propagated circulating tumor cells uncovers the role of NFκB and COP1 in metastasis}},
  year = {2022},
  doi = {10.1101/2022.12.09.519805},
  howpublished = {bioRxiv},
}
Figure